Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31 results about "Bradykinin receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The bradykinin receptor family is a group of G-protein coupled receptors whose principal ligand is the protein bradykinin. There are two Bradykinin receptors: the B₁ receptor and the B₂ receptor.
Antagonists of the bradykinin B1 receptor
InactiveUS20050215470A1Improved pharmacokinetic propertiesKallidin/bradykinin ingredientsSenses disorderMedicineBioactive peptide
The present invention relates to certain biologically active peptides and conjugated peptides which can be used as therapeutics or prophylactics against diseases or conditions linked to B1 as the causative agent. In a preferred embodiment of the invention biologically active PEG-conjugated peptides are provided. In one aspect of the present invention, pharmacologically active PEG-conjugated peptides of the present invention are useful to treat inflammation or pain.
Owner:AMGEN INC
Novel compounds useful for bradykinin B1 receptor antagonism
InactiveUS20070032475A1Relief from maladyEffective treatment and preventionBiocideSenses disorderDiseaseAntagonism
Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor.
Owner:ELAN PHARM INC
Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
Non-peptide compounds of formula (I) having activity as specific antagonists of bradykinin (BK) B2 receptor. The compounds are chemically characterized by the presence of an alpha, alpha-disubstituted amino acid at least one amino group, free or salified, or the corresponding ammonium quaternary salt. These BK receptor antagonists are a novel class of medicaments which can be used in all the disorders in which said receptors are involved
Owner:MENARINI RICHERKE SPA
Substituted Sulfonamide Compounds
Substituted sulfonamide compounds with bradykinin receptor (B1R) modulating activity; processes for the preparation thereof, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or inhibit pain and / or other disorders and / or disease states.
Owner:GRUNENTHAL GMBH
Antagonists of the bradykinin B1 receptor
Owner:AMGEN INC
Spiro group-containing amide compounds having bradykinin 1 receptor (B1R) activity
Substituted spiroamide compounds corresponding to formula (I):wherein A, B, Q1, Q2, Q3, Q4, R1, R8, R9a, R9b, R12, R13, R200 and R210 have defined meanings, processes for their preparation, pharmaceutical compositions containing such compounds, and the use of such compounds for treating or inhibiting pain or other conditions mediated at least in part by the bradykinin 1 receptor (B1R).
Owner:GRUNENTHAL GMBH
Substituted spiro-amide compounds
Owner:GRUNENTHAL GMBH
Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucoma
InactiveUS7807629B1High potencyImprove efficacyHormone peptidesSenses disorderAgonistOcular hypertension
The invention provides methods for treating and / or preventing ocular disorders associated with increased intraocular pressure comprising administering a bradykinin B2 receptor agonist to a patient in need thereof.
Owner:ALCON RES LTD
Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles
Substituted benzimidazoles, benzothiazoles and benzoxazoles, processes for their preparation, pharmaceutical compostions containing these compounds and the use of these compounds for treating or inhibiting disorders or disease states mediated at least in part by bradykinin receptor 1 (BR1).
Owner:GRUNENTHAL GMBH
Therapeutic use of agonists or antagonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth
ActiveUS20130136717A1Increasing concentration and half-lifeGood pharmacological propertiesOrganic active ingredientsHormone peptidesBradykinin receptorCvd risk
The present invention relates to bradykinin receptor modulators and pharmaceutical compositions thereof for use as a medicament for modulating collateral blood vessel growth of collateral arteries and / or other blood vessels of pre-existing arterial networks. The bradykinin receptor modulators of arteriogenesis are applicable in the treatment and / or prevention of disorders associated with defective blood flow or blood vessel malformation. A preferred aspect of the invention relates to bradykinin receptor agonists for use as a medicament for the prevention of cardiovascular ischemic disease in a patient at risk thereof. Further, the invention relates to a bradykinin receptor agonist for use in a method for treating a cardiovascular ischemic disease in a patient in need thereof, wherein said cardiovascular ischemic disease is a peripheral limb disease.
Owner:MAX DELBRUECK CENT FUER MOLEKULARE MEDIZIN
Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucoma
InactiveUS8263555B2High potencyImprove efficacyHormone peptidesSenses disorderIntra ocular pressureBradykinin receptor
The invention provides methods for treating and / or preventing ocular disorders associated with increased intraocular pressure comprising administering a bradykinin B2 receptor agonist to a patient in need thereof.
Owner:ALCON RES LTD
Substituted Disulfonamide Compounds
Substituted disulfonamide compounds corresponding to formula I:In which R1, R2, R3, R4a, R4b, R5a, R5b, R8, R9a, R9b, R10, R11, a, b, s, t and A have defined meanings, pharmaceutical compositions containing one or more such compounds, processes for preparing such compounds, and a method of using such compounds for the treatment or inhibition of pain and / or other conditions mediated by the bradykinin receptor 1 (BR1).
Owner:GRUNENTHAL GMBH
Method for predicting angiotonin II receptor agonist hypotensor medicine function and its use
InactiveCN1858243AImprove efficiencyImprove securityMicrobiological testing/measurementSide effectBradykinin receptor
The present invention provides a kind of reagent kit including reagent for detecting the polymorphic site genotype of bradykinin receptor gene of nucleic acid template. By means of PCR-RFLP method or Taqman method, the detection is fast, safe, convenient, sensitive and reliable. The detection can predict the hypotensive effect of angiotonin II receptor 1 agonist hypotensor and predict the blood fat state of the primary hypertension patient, so that the medicine may be selected based on the individual difference to raise clinical treating efficiency and safety and lower the toxic side effect risk and treating cost.
Owner:ANHUI PROV INST OF BIOLOGICAL MEDICINE +1
Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma
The invention provides compositions and methods for treating and / or preventing ocular disorders associated with increased intraocular pressure. In particular, the compounds are bradykinin agonists.
Owner:ALCON RES LTD +1
Anti-bradykinin b2 receptor (BKB2R) monoclonal antibody
InactiveUS20140017242A1Treat high blood pressurePrevent cancerSenses disorderNervous disorderDiabetes mellitusMonoclonal antibody
The present invention relates generally to anti-bradykinin B2 receptor (BKB2R) antibodies and methods for making and using them. In particular, the anti-BKB2R antibodies having the variable region sequences described herein are useful for altering one or more of BKB2R of and / or GSK-3 signaling pathways for the treatment of diseases, disorders and conditions such as cancer, diabetes, cardiovascular disorders and other conditions.
Owner:DIAMEDICA INC
Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
Non-peptide compounds having activity as selective antagonists of bradykinin (BK) B2 receptor. The compounds are chemically characterized by the presence of an amino acid alpha substituted with a cyclic group and by a tetraalkylammonium group.
Owner:意大利卢索药品研究有限公司
Substituted benzimidazoles, benzothiazoles and benzoxazoles
Owner:GRUNENTHAL GMBH
Substituted Tetrahydropyrrolopyrazine Compounds
Tetrahydropyrrolopyrazine compounds, methods for their preparation, pharmaceutical compositions containing such compounds, and a method of using such compounds for the treatment of pain and other conditions mediated at least partially by Bradykinin 1 receptors (B1R).
Owner:GRUNENTHAL GMBH
Therapeutic use of agonists or antagonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth
ActiveUS9492495B2Increasing concentration and half-lifeGood pharmacological propertiesHormone peptidesOrganic active ingredientsBradykinin receptorAgonist
Owner:MAX DELBRUECK CENT FUER MOLEKULARE MEDIZIN
Novel compounds useful for bradykinin B1 receptor antagonism
InactiveUS20060217362A1Relief from maladySuitable use in blockingBiocideOrganic chemistryBradykinin receptorDisease cause
Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
Owner:ELAN PHARM INC
Use of non-peptidic bradykinin receptor agonists to treat ocular hypertension and glaucoma
The invention provides methods for treating and / or preventing ocular disorders associated with increased intraocular pressure comprising administering a non-peptide bradykinin agonist to a patient in need thereof.
Owner:ALCON RES LTD
Antagonists of the bradykinin B1 receptor
Owner:AMGEN INC
Dynorphin A analogs with bradykinin receptors specificity for modulation of neuropathic pain
ActiveUS10428115B2Relief the painNervous disorderPeptide/protein ingredientsBradykinin receptorNeuropathic pain
Described are Dynorphin A analog compounds and uses thereof for treating pain in humans and lower animals by administering to a human or lower animal in need of treatment. The compounds interact with the bradykinin receptor to relieve pain. Preferred compounds are amphipathic [Des-Arg7]-dynorphin A peptide analogs and specific cyclic dynorphin A peptide analogs.
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA
Novel multitarget drug for treating diseases in mammals
ActiveUS20210284600A1Reduce deathReduce mortalityOrganic active ingredientsOrganic chemistryDiseaseHave Nausea
The invention relates to the chemistry of organic compounds, pharmacology and medicine and concerns therapy for obesity, psoriasis, Crohn's disease, colitis, irritable bowel syndrome, diarrhea, nausea and vomiting, as well as a number of other diseases associated with the activity of cathepsin S, cannabinoid receptors type 1, tachykinin receptors type 1 and 2, prokineticin receptors type 1 and 2, bradykinin receptors type 1, melanocortin receptors MC4R, serotonin receptors 5-HT2B and NB-kB signaling pathway, by using benzyl (2S)-2-[2-(4-hydroxyphenyl)acetamido]-3-phenylpropanoate compound.The compound and pharmaceutically acceptable adducts, hydrates and solvates thereof are a cathepsin S inhibitor, cannabinoid receptor type 1 agonist, tachykinin receptor type 1 and 2 antagonist, prokineticin receptor type 1 and 2 antagonist, bradykinin receptor type 1 antagonist, melanocortin receptor MC4R antagonist, serotonin receptor 5-HT2B antagonist, and NB-kB signaling pathway inhibitor. The invention also relates to pharmaceutical compositions comprising a therapeutically effective amount of the compound according to the invention.
Owner:PHARMENTERPRISES EURASIA LLC
Substituted sulfonamide compounds
Owner:GRUNENTHAL GMBH
Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
Owner:意大利卢索药品研究有限公司
Substituted disulfonamide compounds
Substituted disulfonamide compounds corresponding to formula I:In which R1, R2, R3, R4a, R4b, R5a, R5b, R8, R9a, R9b, R10, R11, a, b, s, t and A have defined meanings, pharmaceutical compositions containing one or more such compounds, processes for preparing such compounds, and a method of using such compounds for the treatment or inhibition of pain and / or other conditions mediated by the bradykinin receptor 1 (BR1).
Owner:GRUNENTHAL GMBH
Antagonists of the bradykinin B1 receptor
The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.
Owner:AMGEN INC
Bioassay method
PendingUS20220317111A1Determine inhibition efficacyEnhanced signalCompound screeningApoptosis detectionBiologic AssaysAssay
The present invention relates to a determination of antagonist effect of desired compound useful in the inhibition of activity of bradykinin receptors. Furthermore, the present invention provides an improved assay method to determine the efficacy of desired compounds by inhibiting the activity of bradykinin receptors. More specifically the present invention provides an improved assay method, wherein desired antagonistic effect of the compounds is determined by measuring intracellular calcium release.
Owner:KASHIV BIOSCIENCES LLC
Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma
The invention provides compositions and methods for treating and / or preventing ocular disorders associated with increased intraocular pressure. In particular, the compounds are bradykinin agonists.
Owner:ALCON RES LTD +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com